Drug Approval | January 23, 2023
Astellas announces hold lifted by FDA on Fortis clinical trial of AT845
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
Subscribe To Our Newsletter & Stay Updated
